## SEQUENCE LISTING

<110> ONCOTHERAPY SCIENCE, INC. JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO	
<120> Method for cell injuring using effector function of anti FAM3D antib	ody.
<130> ONC-A0407-US	
<160> 2	
<170> PatentIn version 3.1	
<pre>&lt;210&gt; 1 &lt;211&gt; 1322 &lt;212&gt; DNA &lt;213&gt; Homo sapiens</pre>	
<220> <221> CDS <222> (298) (972) <223>	
<ul> <li><a href="text-align: left;">(400)</a> 1</li> <li>tcctcaaagg agggcagag cctgcgcagg gcaggagcag ctggcccact ggcggcccgc aacactccgt ctcacctct gggcccactg catctagagg agggccgtct gtgaggccac tacccctcca gcaactggga ggtgggactg tcagaagctg gcccagggtg gtggtcagct gggtcaggga cctacggcac ctgctggacc acctcgcctt ctccatcgaa gcagggaagt gggaggcctcg agccctcggg tggaagctga ccccaagcca cccttcacct ggacagg 297</li> </ul>	
atg aga gtg tca ggt gtg ctt cgc ctc ctg gcc ctc atc ttt gcc ata  Met Arg Val Ser Gly Val Leu Arg Leu Leu Ala Leu Ile Phe Ala Ile  1 5 10 15	
gtc acg aca tgg atg ttt att cga agc tac atg agc ttc agc atg aaa Val Thr Trp Met Phe Ile Arg Ser Tyr Met Ser Phe Ser Met Lys 20 25 30	
acc atc cgt ctg cca cgc tgg ctg gca gcc tcg ccc acc aag gag atc Thr Ile Arg Leu Pro Arg Trp Leu Ala Ala Ser Pro Thr Lys Glu Ile 35 40 45	

gtt Val 50														489
ttt Phe					-	-								537
atg Met														585
 ggc Gly								Val				Gly		633
ctg Leu							Met				Val			681
gtg Val 130						lle				Leu				729
tcc Ser					Gly				Asp					777
ttc Phe	Ser	Asp		Gly	Ser	Ser	Tyr	Ala	Gln				Arg	825
agc Ser			Phe					Asp				Ser		873
		Phe					Pro				Tyr		gga Gly	921
cca Pro													ttt Phe	969

1022

1082

1142

1202 1262

1322

220 215 210 tag ggtggctgtg gctcttcctc agccaggggc ctgaagaagc tcctgcctga cttaggagtc agagcccggc aggggctgag gaggaggagc agggggtgct gcgtggaagg tgctgcaggt ccttgcacgc tgtgtcgcgc ctctcctct cggaaacaga accctcccac agcacatect acceggaaga ceagecteag agggteette tggaaceage tgtetgtgga gagaatgggg tgctttcgtc agggactgct gacggctggt cctgaggaag gacaaactgc ccagactiga gcccaattaa attitattit tgctggtttt gaatgaaaaa aaaaaaaaaa <210> 2 **<211> 224** <212> PRT <213> Homo sapiens <400> 2 Met Arg Val Ser Gly Val Leu Arg Leu Leu Ala Leu Ile Phe Ala Ile 5 10 15 Val Thr Thr Trp Met Phe Ile Arg Ser Tyr Met Ser Phe Ser Met Lys 30 20 25 Thr Ile Arg Leu Pro Arg Trp Leu Ala Ala Ser Pro Thr Lys Glu Ile 45 35 40 Gln Val Lys Lys Tyr Lys Cys Gly Leu Ile Lys Pro Cys Pro Ala Asn 50 55 60 Tyr Phe Ala Phe Lys Ile Cys Ser Gly Ala Ala Asn Val Val Gly Pro 80 75 65 70 Thr Met Cys Phe Glu Asp Arg Met Ile Met Ser Pro Val Lys Asn Asn 85 Val Gly Arg Gly Leu Asn Ile Ala Leu Val Asn Gly Thr Thr Gly Ala 100 105

Val Leu Gly Gln Lys Ala Phe Asp Met Tyr Ser Gly Asp Val Met His

Leu Val Lys Phe Leu Lys Glu Ile Pro Gly Gly Ala Leu Val Leu Val

120

115

125

130	135	140
1.30	135	140

Ala Ser Tyr Asp Asp Pro Gly Thr Lys Met Asn Asp Glu Ser Arg Lys 145 150 155 160

Leu Phe Ser Asp Leu Gly Ser Ser Tyr Ala Lys Gln Leu Gly Phe Arg 165 170 175

Asp Ser Trp Val Phe Ile Gly Ala Lys Asp Leu Arg Gly Lys Ser Pro 180 185 190

Phe Glu Gln Phe Leu Lys Asn Ser Pro Asp Thr Asn Lys Tyr Glu Gly 195 200 205

Trp Pro Glu Leu Leu Glu Met Glu Gly Cys Met Pro Pro Lys Pro Phe 210 215 220